Recurrent gene fusions in prostate cancer

• US 8,969,527 B2
• Filed: 05/30/2012
• Issued: 03/03/2015
• Est. Priority Date: 09/12/2005
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated, Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Tomlins, Scott, Rhodes, Daniel, Chinnaiyan, Arul, Mehra, Rohit, Rubin, Mark A., Sun, Xiao-Wei, Perner, Sven, Lee, Charles, Demichelis, Francesca
• Primary Examiner(s): Yao, Lei
• Application Number:
  US13/483,142
• Publication Number:
  US 20120296070A1
• Time in Patent Office: 1,007 Days
• Field of Search: None
• US Class Current: 530/387.1
• CPC Class Codes: A01K 2217/072 maintaining or altering function, i.e. knock in
• CPC Class Codes: A01K 2217/206 Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/0331 Animal model for proliferative diseases
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 9/6424 Serine endopeptidases (3.4.21)
• CPC Class Codes: C12N 9/6445 Kallikreins (3.4.21.34; 3.4.21.35)
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57434 of prostate
• CPC Class Codes: Y10S 435/81 : Packaged device or kit

Abstract

Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.

Claims

1. A composition comprising an antibody that is specific for a truncated ERG1 protein, wherein the truncated ERG1 protein has an amino acid sequence that begins at a methionine that is the 47th amino acid of SEQ ID NO:

240 and the antibody binds an epitope comprising the 47th amino acid of SEQ ID NO;

240.

2. The composition of claim 1, wherein the truncated ERG1 protein is encoded by a gene fusion resulting from rearrangement of TMPRSS2 and ERG1 genes.

3. The composition of claim 2, wherein the gene fusion comprises a 5′

portion from the TMPRSS2 gene and a 3′

portion from the ERG1 gene.

4. The composition of claim 3, wherein the gene fusion comprises a 5′

portion from a transcriptional regulatory region of the TMPRSS2 gene.

5. The composition of claim 4, wherein the transcriptional regulatory region comprises a promoter region of the TMPRSS2 gene.

6. A composition comprising an antibody that binds an epitope comprising the 47th amino acid of SEQ ID NO:

240.

7. The composition of claim 6 wherein said epitope results from a gene fusion resulting from the fusion of, rearrangement of TMPRSS2 and ERG1 genes.

8. A composition comprising an antibody that binds an epitope comprising the 47th amino acid of SEQ ID NO:

240 that is a truncated ERG1 protein encoded by a gene fusion resulting from rearrangement of TMPRSS2 and ERG1 genes.

9. The composition of claim 8, wherein the gene fusion comprises a 5′

portion from the TMPRSS2 gene and a 3′

portion from the ERG1 gene.

10. The composition of claim 9, wherein the gene fusion comprises a 5′

portion from a transcriptional regulatory region of the TMPRSS2 gene.

11. The composition of claim 10, wherein the transcriptional regulatory region comprises a promoter region of the TMPRSS2 gene.